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Abstract
p21-activated kinases (PAKs) are important regulators of cell motility and morphology. It has been
challenging to interrogate their functions because cells adapt to genetic manipulation of PAK, and because
inhibitors act on multiple PAK isoforms. Here we describe genetically encoded PAK1 analogues that can
be selectively activated by the membrane-permeable small molecule rapamycin. An engineered domain
inserted away from the active site responds to rapamycin to allosterically control activity of the PAK1
isoform. To examine the mechanism of rapamycin-induced PAK1 activation, we used molecular dynamics
with graph theory to predict amino acids involved in allosteric communication with the active site. This
analysis revealed allosteric pathways that were exploited to generate kinase switches. Activation of PAK1
resulted in transient cell spreading in metastatic breast cancer cells, and long-term dendritic spine
enlargement in mouse hippocampal CA1 neurons.
Keywords: allosteric switch, protein dynamics, PAK, cell motility, dendritic spines
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INTRODUCTION
P21-activated kinases (PAK1–6) are serine/threonine kinases involved in cytoskeletal signaling networks.
PAKs have been shown to regulate cell morphodynamics in angiogenesis, synaptic transmission,
neurogenesis, and metastasis.  The role of PAK1 activation kinetics, and the specific roles of different
PAK isoforms, remain unclear. PAK inhibitors have been used to probe the roles of PAKs in living
systems, but their target specificity is debated.
We previously developed an approach to activate kinases using rapamycin or its non-immunosuppressive
analogs, applied to the Src family kinases Src, Yes and Fyn, to mitogen-activated kinase p38, and to focal
adhesion kinase.  An engineered rapamycin-binding domain was inserted into a surface-exposed loop of
the kinase, where its conformational changes were coupled allosterically to the active site. The domain
destabilized the ATP binding loop (G-loop) of the kinase, disrupting activity. Rapamycin binding led to
restabilization and kinase activation. Here we engineer rapamycin-sensitive switches specifically for the
PAK1 isoform, and study the effects of PAK1 activation on cancer cell morphodynamics and hippocampal
neuron spine formation. In contrast to the kinases previously targeted,  PAK is a homodimer in its
inactive state.  We have identified an additional allosteric site for domain insertion and shed light on the
allosteric mechanism used by the engineered domains.
RESULTS AND DISCUSSION
In the present study, we focus on PAK1 because it is the dominant isoform upregulated in human tumors,
and it is one of the PAK isoforms expressed in brain. PAK1 consists of a C-terminal kinase domain, and
regulatory domains that include a p21-binding domain (PBD) and an inhibitory domain (AI). We produced
both dual and single chain PAK1 switches, targeting the kinase domain in both cases (Figure 1A and B). In
the dual chain design, we used FK506-binding-protein (FRB) protein together with the insertable FKBP12
domain (iFKBP).  The iFKBP domain was inserted at an allosteric site within the catalytic domain,
causing kinase inactivation. Addition of rapamycin induced binding between the kinase-iFKBP chimera
and co-expressed FRB, resulting in stabilization and reactivation of the kinase. This design was named
rapamycin-regulated PAK1 (RapR PAK1, Figure 1A). In the single chain or unimolecular (uniRapR)
design, a single domain combining iFKBP and FRB was inserted at the allosteric site; this similarly
conferred rapamycin regulated activity (Figure 1B). The dual-chain design is advantageous in that it can
be used to cause activated PAK1 to interact with specific target molecules.  The single-chain design is
more convenient for simple PAK1 activation and does not show heterogeneous responses stemming from
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varied expression ratios of the two chains.  The insertion site previously used successfully for other
kinases was tested first. This site is not evolutionary conserved (Figure S1), and does not interact with the
regulatory domain, the dimerization interface (Figure 1C), or any other structural elements in the protein
(Figure S2). These characteristics led us to choose the 288–293 PAK1 loop for insertion of the engineered
domains.
Figure 1
Engineering rapamycin-responsive PAK1 analogs
In order to increase kinase activity upon activation, and to remove any PAK1 regulation other than simple
rapamycin-induced activation, we introduced phosphomimetic S422D/T423E mutations into PAK1 to
render it constitutively active. Our previous work showed that flexible linkers between the rapamycin
sensitive domain and the host protein enable folding of the two domains, but reduce effective allosteric
transmission from the sensory domain to the host protein. Conversely, short linkers increase the efficiency
of allosteric transmission, but can restrain proper folding of two domains.  Considering these
criteria, we tested several linkers between the rapamycin sensitive domain and the kinase domain. For the
dual chain analog, four variants of engineered PAK1 were prepared: 1) iFKBP replacing Ala291 and
connected Gly-Pro-Gly linkers on both sides; 2–3) iFKBP replacing the Asp289-Gly293 residues and
connected using either Gly or Gly-Pro-Gly linkers; 4) iFKBP replacing Met288-Gln294 residues and
connected via Gly-Pro-Gly linkers. We co-expressed each construct with FRB in HEK293T cells and,
following immunoprecipitation of PAK1, tested kinase activity using a PAK1 substrate, MEK1, which is
phosphorylated at residue S298.  Replacement of Asp289-Gly293 with iFKBP flanked by GPG linkers
produced optimal rapamycin regulation of engineered PAK1 (Figure S3). We named this optimized
version rapamycin-regulatable PAK1 (RapR-PAK1). FRB was present in the pull-down samples, showing
binding of FRB to PAK1-iFKBP. In control experiments, constitutively active PAK1 alone did not respond
to rapamycin, and kinase-dead PAK1 alone was inactive in the absence or presence of rapamycin (Figure
S3). These experiments demonstrated that insertion of the iFKBP domain into the loop between residues
288 and 293 generated a robust, regulatable dual chain PAK1 analog. We next made a single chain
rapamycin-responsive PAK1 by replacing iFKBP with the uniRapR domain. To increase the dynamic
range of uniRapR-PAK1, we introduced a mutation (L107F) on the interface that enhanced PAK1 activity
(Figure S3).  We directly compared the dual chain RapRPAK1 with the single chain uniRapR-PAK1 by
monitoring the phosphorylation of endogenous MEK1 upon addition of rapamycin into the cell medium.
Similar to RapR-PAK1, uniRapR-PAK1 was inactive without rapamycin and was activated by rapamycin (
Figure 1D). In vitro kinase assays demonstrated regulation of UniRapR-PAK1 by rapamycin (Figure S3).
These results showed that both the dual and single chain PAK1 analogs could be efficiently activated in
living cells by rapamycin.
PAK1 has been identified as an oncogene that transforms breast epithelial cells,  and overexpression of
mutant PAK1 increases the migration rates of breast cancer cells.  To test the effects of PAK1 kinase
activity on breast cancer cell morphodynamics, we expressed uniRapR-PAK1 in the metastatic basal B
triple-negative breast cancer cell line MDA-MB-231 and measured the area of cells 5, 20, and 60 minutes
after rapamycin addition. The cells showed an increase in area within 5 minutes of Pak1 activation (
Figure 1E) but later returned to their original morphology within 20 minutes. Previous studies suggested
that LIM kinase 1 (LIMK1), a substrate of PAKs, might contribute to the invasive behavior of breast
cancer cells.  Consistent with this hypothesis, phosphorylation of LIMK was also maximized at the 5-
minute time point and decreased at the 20-minute time point (Figure 1F). Control cells exhibited no
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response to rapamycin. These results demonstrate the ability of RapR PAK1 to control cell morphology,
support a role for the PAK1 isoform in motility and metastasis, and indicate that PAK1 activity alone is not
sufficient to induce cell polarization and motility.
PAK1 has been shown to be involved in neuronal spine morphology, synaptic transmission, and
pathological conditions including mental retardation and schizophrenia.  The kinase activity of PAK is
important in brain physiology, because PAK inhibitors have been shown to ameliorate schizophrenia-
associated dendritic spine deterioration.  It remains unclear which isoform is responsible for these
effects. We previously showed that in vivo activation of Rac1, an activator of PAK, leads to spine
shrinkage in the neocortex.  We therefore asked how acute rapamycin-regulatable activation of PAK1
leads to the morphological changes of dendritic spines in the hippocampus. We expressed RapR-PAK1-
EGFP in hippocampal CA1 neurons (Figure 2A), and observed that activation of PAK1 led to long-term
dendritic spine enlargement (> 40 min) (Figure 2B). Although each spine responded to rapamycin with
different kinetics (Figure 2C), there was an overall persistent increase in the spine volume (area of change
60% ± 15%, n = 35 spines), whereas neurons expressing only EGFP did not respond to rapamycin (n = 13
spines) (Figure 2D and E). Based on these results, we concluded that acute activation of PAK1 leads to
long-term dendritic spine enlargement, suggesting insights into the roles of the PAK1 isoform in long-
term-potentiation, learning and memory.
Figure 2
Enlargement of dendritic spines induced by rapamycin
Our previous molecular dynamic modeling of focal adhesion kinase showed that the iFKBP insertion loop
moves in concert with the kinase G-loop.  We hypothesized that residues which move in concert are
allosterically coupled, so loops that move in concert with the active site are good candidates for insertion
of an allosteric control domain. To test this hypothesis, we analyzed PAK1 kinase domain using discrete
molecular dynamics.  In Figure 3A, the correlation coefficients for the motions of each α carbon pair
are represented as a heat map, showing that motions of the iFKBP insertion loop (L1) correlate with those
of the catalytic site, particularly with the ATP binding G-loop. This analysis also revealed another loop
(L2) whose motions correlated with those of the ATP binding site. Similar to L1, this loop is solvent
exposed and is not evolutionarily conserved (Figure S4). To test whether insertion of the uniRapR domain
into the L2 loop produces an allosteric switch, we substituted residues G337 and D338 in L2 with the
uniRapR domain. Similar to the original PAK1 analog (uniRapR-PAK1-L1), the uniRapR-PAK1-L2
analog responded to rapamycin (Figure 3B). We reduced the slight off-state activity by removing two
residues from the loop, V336 and E339 (Figure 3B). These results, along with linker optimization of the
first analog (Figure S3), showed that on/off state activity can be adjusted through linker optimization (
Figure 3B). For PAK1, shortening the loop or removing residues from the insertion loop reduced off state
activity, and on state activity was increased by elongating the loop using flexible residues. We also
inserted the uniRapR domain into two additional loops (L3 and L4). Like L1 and L2, L3 connects two β-
strands that interact with ATP, and its motion correlates with the motions of ATP binding sites (Figure S5).
In contrast, L4 is in the flexible linker connecting two lobes of the kinase. Biochemical assays showed that
insertion of uniRapR into L3 generated rapamycin-dependent PAK1 activity, whereas the PAK1 analogue
produced by inserting uniRapR into L4 was not affected by insertion or rapamycin. This data showed that
a PAK1 switch could be generated by inserting uniRapR into loops whose motions correlated with the
motions of the catalytic site.
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Figure 3
Understanding the mechanism of allosteric propagation to
generate PAK1 analogs
We hypothesized that the inserted allosteric switch affected the active site because changes in switch
movement affected active site movement. Residues that move in concert throughout the kinase domain
may constitute an allosteric path to propagate changes between engineered domains and the active site. To
track such propagation pathways, we used a graph theory, converting motion dynamics of residues into an
undirected network in which nodes represent residues, edges represent contacts, and edge weights are
correlation coefficients (Figure 3B). The shortest path from insertion loops L1 or L2 to the catalytic site
was calculated using Dijkstra’s algorithm (Figure 3C),  indicating that the propagation from L1 is
transmitted through the strands located between residues G293-Q300 and G282-D289 (Figure 3D).
Interestingly, such intra-strand propagation is not present in the case of L2, where the perturbation is
propagated in an inter-strand manner between strands E339-E345, G293-N302, D282-D289, and E274-
D289 (Figure 3D and E). As an alternative approach, we analyzed potential allosteric pathways using co-
evolution of residues,  as previously described.  Prediction of residues that coevolve with the catalytic
site indicated a similar inter-strand pathway (Figure S6). Correlated motions in ß-sheets have been
suggested to be fundamental for allosteric regulation of protein function.  Together these results showed
that perturbation is propagated from our two insertion loops (L1 and L2) via intra-strand and inter-strand
pathways, respectively. This notion will be helpful for generation of new kinase switches, and for
application to other protein families.
EXPERIMENTAL PROCEDURES
DNA constructs
All restriction enzymes were purchased from New England Biolabs. pmVenus-N1-PAK1 was a gift from
Jonathan Chernoff. Point mutations and insertions of iFKBP and uniRapR sequences into PAK1 were done
with the Quikchange mutagenesis kit (Stratagene). Retroviral plasmids were generated by cloning
uniRapR-PAK1-mCherry into pBABE-Tet-Off-puro plasmid (Clontech).
Biochemical characterization of the kinase activity
Cell transfection, immunoprecipitation, and testing kinase activity were performed as described
previously.  See Supplemental Experimental Procedures for details. HEK293 cells were transfected with 1
µg of DNA constructs using Fugene 6 reagent (Roche) using manufacturer’s guidelines. After 24 hours of
transfection, cells were treated with either rapamycin (Sigma) or an equivalent volume of ethanol for 30
minutes. Cells were lysed with lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100 and
Roche protease inhibitor cocktail). Endogenous phosphorylation of MEK was detected by Western
blotting. For immunoprecipitation experiments, cleared lysates were incubated with protein-G beads
attached to anti-GFP antibody (JL8, Clontech) for 2 hours. The beads were washed three times with lysis
buffer, and then with kinase buffer (2 mM Tris, pH 8.0, 10 mM MgCl ) for phosphorylation assays. 800
ng purified MEK, ATP (100 µM) in 40 µL of kinase buffer containing 1 µM of dTT were mixed with bead
suspension for 10 minutes at 30° C. Reactions were quenched by adding sample loading buffer and boiling
for 5 minutes. Phosphorylated MEK was detected in pull-down samples by Western blotting using anti-
pMEK-S298 and anti-MEK1/2 antibodies (Cell Signaling).
Imaging of MDA-MB-231 cells
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After 2 days without doxcyline, cells were seeded at 10,000 cells per well in DMEM with puromycin on
fibronectin coated coverslips (10µg/ml). The next morning (about 6 hours before the experiment), cell
media was replaced with DMEM (2% FBS), with 450µl in each well of a 4 well plate. Cells were
incubated with 500 nM rapamycin for 5, 20, and 60 minutes. Cells were then fixed in 4% PFA (in PBS)
and stained with DAPI (1:10000) and phalloidin Alexa488 (1:1000). Cells were imaged with an Olympus
IX71 inverted microscope.
Imaging of mouse hippocampal cells
Hippocampal slices with a thickness of 350 µm were prepared from 7-day-old Sprague-Dawley rats.
Slices were mounted on 0.4-µm culture inserts (Millipore, Billerica, MA) and incubated at 35°C under 5%
CO  in a medium consisting of 50% MEM (Invitrogen, Carlsbad, CA), 25% Hanks’ balanced salt solution
(Invitrogen), 25% horse serum (Nichirei, Tokyo, Japan), and glucose (6.5 g/l) (Nacalai Tesque, Kyoto,
Japan). After 4 days in culture, the slices were transfected with a Gene Gun system (PDS-1000; Bio-Rad,
Hercules, CA) with RapR-PAK-Venus and FRB-mCherry. Imaging experiments were performed 3 days
after the transfection. Each culture insert was transferred to a recording chamber and superfused with a
solution (ACSF) that contained 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl , 1 mM MgCl , 1.25 mM
NaH PO , 26 mM NaHCO , 20 mM glucose, 1uM TTX, and 200uM Trolox, and had been equilibrated
with 95% O  and 5% CO . Rapamycin (Wako, Tokyo) was applied through bath perfusion. All
physiological experiments were performed at room temperature (23° to 25°C). The experiments were
approved by the Animal Experiment Committee of the Faculty of Medicine, University of Tokyo. Two-
photon imaging of dendritic spines was performed with an upright microscope (BX61WI; Olympus,
Tokyo, Japan) equipped with a FV1000 laser-scanning microscope system (FV1000, Olympus) and a
water-immersion objective lens (LUMPLFLN60xW, numerical aperture 0.9). We use a mode-locked,
femtosecond-pulse Ti:sapphire lasers (MaiTai from Spectra Physics, Mountain View, CA; Chameleon
from Coherent, Santa Clara, CA) with a wavelength of 970 nm. Emitted fluorescence was acquired at 488
to 560 nm and 590 to 680 nm for Venus and mCherry, respectively. Three-dimensional reconstructions of
dendritic morphology were generated by the summation of Venus fluorescence values separated by 0.5
µm. The spine-head volumes were estimated from the total fluorescent intensity.
Molecular modeling, discrete molecular dynamics, and correlative motion analysis
The crystal structure of the kinase domain was obtained from the Protein data bank (PDB id: 1f3m), and
Medusa Toolkit was used to model the protein.  All simulations were performed using all-atom discrete
molecular dynamics.  Atomic clashes were corrected and the protein was minimized at heat exchange
coefficient 10 at 0.7 kcal/mol·k  with a harmonic potential constant of 1 kcal/mol•A . The system was
then packed at 0.3 kcal/mol·k  with heat exchange coefficient 1. Upon packing, the system was simulated
at 0.4 kcal/mol·k  for 1 million DMD steps.  Cα represent nodes of the graph, edges represent the
connection between nodes. Edge weight is based on the correlation coefficient calculated by correlative
motion analysis. The shortest distance between two selected residues were calculated by Dijkstra’s
algorithm.
Sequence conservation and co-evolution analysis
Pfam was used to obtain protein kinase domain sequences.  The MISTIC server was used to calculate
sequence conservation and co-evolving mutual information.
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Supplemental Information
Figures S1–S6. Pak structures showing important domains, sites of insertion, and their properties.
Assays showing control of kinase activity with insertion at different sites. Coevolved residues in the
kinase domain.
Click here to view.
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